July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Sergio Cifuentes Canaval: My takeaways from new analysis of the CheckMate 9ER trial
May 9, 2024, 09:54

Sergio Cifuentes Canaval: My takeaways from new analysis of the CheckMate 9ER trial

Sergio Cifuentes Canaval, Cancer Research Project Manager at 

“Nivolumab + Cabozantinib: Numbers Confirm Efficacy in Advanced Kidney Cancer: CM 9ER

New analysis of the CheckMate 9ER trial, here are my takeaways:

Survival:
Nivolumab + Cabozantinib significantly improved both PFS and OS compared to Sunitinib.
– PFS: 16.6 m vs 8.4 m (HR 0.59; 95% CI 0.49-0.71)
– OS: 49.5 m vs 35.5 m (HR 0.70; 95% CI 0.56-0.87)

Response Rates:
Patients receiving Nivolumab + Cabozantinib reached a
– CR: 13% vs 5%
– ORR: 56% (50-62%) vs 28% (23-33%)
– mDoR: 22.1 m vs 16.1 m

Benefit Across Risk Groups:
The combination therapy showed benefits for patients in intermediate, poor, and intermediate/poor risk groups based on the IMDC score.

Higher Impact for High-Risk Patients (IMDC score high).

Significant Mexican Participation: We’re proud to note that a significant portion of the study population (35%) were from Mexico!”

Source: Sergio Cifuentes Canaval/LinkedIn